EDITNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Editas Medicine, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$2.42+0.07 (+2.98%)

Close on Oct 19, 2026

Market cap: $288.69M
P/E (TTM): –
Dividend yield: –

Editas Medicine, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Cash & Equivalents	147	135	128	142	207	144	240	136	148	187	144	11	2.01
Short-Term Investments	0	138	199	203	296	262	219	234	183	–	–	–	–
Cash & Short-Term Investments	147	274	327	344	504	406	459	371	331	187	144	11	2.01
Receivables	15	16	10	5.15	0.27	6.05	0.42	0.03	0.68	0.09	1.02	–	–
Prepaid Expenses & Other	2.07	3.14	7.53	7.34	7.20	11	6.29	5.79	2.38	1.77	0.79	–	–
Total Current Assets	164	289	341	357	507	419	464	375	332	187	145	–	–
Property, Plant & Equipment	3.54	14	12	16	17	14	11	40	39	40	2.13	–	–
Gross Property, Plant & Equipment	32	46	38	37	33	25	18	47	44	42	2.76	–	–
Accumulated Depreciation	-28	-32	-26	-22	-16	-11	-7.20	-7.13	-4.06	-1.56	-0.63	–	–
Long-Term Investments	–	0	104	93	120	110	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	16	33	34	44	26	25	29	19	–	–	–	–	–
Other Long-Term Assets	2.98	5.22	8.59	5.25	6.81	4.70	5.39	5.38	1.62	1.62	2.25	–	–
Total Assets	187	342	499	514	677	573	509	420	373	229	149	–	–
Accounts Payable	2.61	5.49	8.27	9.51	5.05	6.41	5.84	5.33	4.02	4.64	1.38	–	–
Accrued Expenses	33	46	35	31	20	24	22	13	11	17	5.46	–	–
Current Portion of Long-Term Debt	5.00	5.00	0	–	–	–	–	–	–	–	–	–	–
Current Debt	5.00	5.00	0	–	–	–	–	–	–	–	–	–	–
Current Portion of Leases	6.03	15	12	11	10	6.81	5.80	3.85	–	–	–	–	–
Deferred Revenue (Current)	0	6.22	8.22	8.22	11	21	24	16	13	0.26	–	–	–
Other Current Liabilities	–	–	–	–	–	–	2.68	2.05	0.90	0.75	–	–	–
Total Current Liabilities	46	77	63	60	47	58	60	36	37	33	6.93	–	–
Long-Term Debt	54	52	0	–	–	–	–	–	–	–	–	–	–
Long-Term Leases	12	20	24	33	16	19	23	16	–	–	–	–	–
Operating Lease Liabilities	18	35	37	44	26	26	29	20	–	–	–	–	–
Other Long-Term Liabilities	2.82	3.07	1.80	0	–	28	0.00	0.29	0.32	0.40	0.03	–	–
Total Liabilities	159	207	150	154	124	179	246	184	165	95	33	–	–
Total Debt	59	57	0	–	–	–	–	–	–	–	–	–	–
Preferred Stock	0	0	0	0	–	–	–	–	–	–	–	–	–
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.00	–	–	–
Additional Paid-In Capital	1,656	1,602	1,580	1,442	1,412	1,059	812	652	514	320	5.23	–	–
Retained Earnings	-1,629	-1,468	-1,231	-1,078	-858	-665	-549	-416	-306	-186	-88	–	–
Comprehensive Income & Other	0	0.27	0.20	-3.60	-0.49	-0.05	0.11	-0.03	-0.08	–	–	–	–
Shareholders' Equity	27	134	349	361	554	394	262	236	208	135	-83	-15	-1.76
Total Equity	27	134	349	361	554	394	262	236	208	135	-83	-15	-1.76
Total Liabilities & Equity	187	342	499	514	677	573	509	420	373	229	149	–	–
Shares Outstanding(shares)	98	83	82	69	68	63	54	49	45	36	3.23	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -161.4%
Net margin: -157.3%
Return on equity, FY2025: -198.1%

Financial strength

Current ratio: 3.19
Debt to equity: 0.53
Debt to assets: 23.5%
Cash to current liabilities: 265.7%

Valuation

P/E ratio: –
Price to sales: 6.14
Price to book: 2.74
Dividend yield: –